The content on this site is intended for healthcare professionals only
Myeloma is a rare cancer primarily affecting older adults, characterised by malignant plasma cells. Symptoms include high calcium levels and renal failure. Treatment has evolved from radiation to modern therapies like immunomodulators and monoclonal antibodies. BCMA is a key receptor on plasma cells, and therapies targeting BCMA show promise. The talk discusses various BCMA-targeted therapies, their effectiveness, and future directions for improving patient outcomes.
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
SIOG 2024: Updates in haematology
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Use of bispecifics and CAR T cells in South America
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
